JMKX 001899
Alternative Names: JMKX-001899Latest Information Update: 17 Jul 2025
At a glance
- Originator Jemincare
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
- Research Colorectal cancer
Most Recent Events
- 06 Jun 2025 Phase-I clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT06946927)
- 27 Apr 2025 Jemincare plans phase I trial in Non small cell lung cancer (Combination therapy, Metastatic disease and Late-stage disease) in China in June 2025 (PO) (NCT06946927)
- 25 Jun 2024 Jemincare plans a phase I trial for Solid tumours (In Volunteers) in July 2024 (PO, tablet) (NCT06473948)